Thank you.
Mr. Alvarez, pretty well every practitioner who has appeared at the committee, when they talked about the reporting of adverse drug events—and I think we're generally hearing that 10% of serious adverse events are being reported now—they told us that they'd be willing to report every, or pretty well every, adverse event if there were a simple, efficient method that fed back to them. I don't know how you would define that, but it should tell them: this is what you should have expected; what you got is reasonable, and you should have expected it; or these are the alternatives you can use. So it would require participation by the practitioner, by Health Canada, but also by the industry, by the manufacturers of these pharmaceuticals and the people who have experience with them.
I'm very pleased to hear of the advances you're making, but will they get us there? Will they result in a two-way dialogue with practitioners?